Axsome up after FDA grants priority review for Alzheimer's agitation drug

Shares of Axsome Therapeutics AXSM.O rise 2.2% to $152 premarket

Drugmaker says that the U.S. FDA has accepted its marketing application for its drug, AXS-05, to treat Alzheimer's disease agitation

Agitation in Alzheimer's disease is a common symptom of emotional distress, marked by restlessness, pacing, verbal outbursts, or physical aggression often triggered by pain, changes in routine, confusion, or feeling overwhelmed

The FDA has granted the application a 'priority review' tag, which is given to drugs that may offer significant improvements in effectiveness or safety for serious conditions

The health regulator is set to decide on the drug on April 30, 2026 - AXSM

Up to last close, stock up 75.8% YTD